SCHEMBL14916610

SCHEMBL14916610

CC(C)(C)CC(=O)C(=NNc1cccc(Br)c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.43
MAOB P27338 3/20 0.41
MAOA P21397 2/20 0.41
SMN1; SMN2 Q16637 6/20 0.41
RAB9A P51151 6/20 0.41
MAPT P10636 6/20 0.41
NPC1 O15118 4/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 3/20 0.39
ALDH1A1 P00352 1/20 0.39
TGM2 P21980 1/20 0.37
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359986 0.82 SMN1; SMN2 (0.53) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL359987 0.82 SMN1; SMN2 (0.53) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL23539268 0.75 GAA (0.47) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL16115788 0.75 GAA (0.47) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL16115787 0.75 GAA (0.47) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL14916611 0.73 RAB9A (0.44) GAASMN1; SMN2RAB9AMAPTNPC1
SCHEMBL10283806 0.73 RAB9A (0.44) GAASMN1; SMN2RAB9AMAPTNPC1
SCHEMBL21069367 0.72 GAA (0.44) GAAMAOBMAOASMN1; SMN2RAB9A
SCHEMBL30041694 0.67 SMN1; SMN2 (0.51) GAASMN1; SMN2RAB9AMAPTNPC1
SCHEMBL23554176 0.67 SMN1; SMN2 (0.51) GAASMN1; SMN2RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET GAA 1452/4885MAOB 1465/4885MAOA 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.